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Abstract
Background: South Africa has over 6,000,000 HIV infected individuals and the province of KwaZulu-Natal (KZN) is
the most severely affected. As public health initiatives to better control the HIV epidemic are implemented, timely,
detailed and robust surveillance data are needed to monitor, evaluate and inform the programmatic interventions
and policies over time. We describe the rationale and design of the HIV Incidence Provincial Surveillance System
(HIPSS) to monitor HIV prevalence and incidence.
Methods/Design: The household-based survey will include a sample of men and women from two sub-districts of
the uMgungundlovu municipality (Vulindlela and the Greater Edendale) of KZN, South Africa. The study is designed as
two sequential cross-sectional surveys of 10,000 randomly selected individuals aged 15–49 years to be conducted one
year apart. From the cross sectional surveys, two sequential cohorts of HIV negative individuals aged 15–35 years will
be followed-up one year later to measure the primary outcome of HIV incidence. Secondary outcomes include the
laboratory measurements for pulmonary tuberculosis, sexually transmitted infections and evaluating tests for estimating
population-level HIV incidence.
Antiretroviral therapy (ART) access, HIV-1 RNA viral load, and CD4 cell counts in HIV positive individuals will assess the
effectiveness of the HIV treatment cascade. Household and individual-level socio-demographic characteristics, exposure
to HIV programmatic interventions and risk behaviours will be assessed as predictors of HIV incidence. The incidence
rate ratio of the two cohorts will be calculated to quantify the change in HIV incidence between consecutive samples.
In anticipation of better availability of population-level HIV prevention and treatment programmes leading to decreases
in HIV incidence, the sample size provides 84 % power to detect a reduction of 30 % in the HIV incidence rate
between surveys.
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Discussion: The results from HIPSS will provide critical data regarding HIV prevalence and incidence in this community
and will establish whether HIV prevention and treatment efforts in a “real world”, non-trial setting have an impact on
HIV incidence at a population level. Importantly, the study design and methods will inform future methods for HIV
surveillance.
Background
The HIV epidemic has reached an unprecedented scale in
southern Africa, with South Africa having the highest
number of infected individuals worldwide. The South Afri-
can National HIV Prevalence, Incidence, Behaviour and
Communication Survey of 2012 estimated that amongst
individuals in the 15–49 year age group, the overall HIV
prevalence was 18.8 % [95 % Confidence interval (CI)
17.5–20.3]. However, HIV is unevenly distributed across
all provinces and the worst affected province is KwaZulu-
Natal (KZN) with a prevalence of 27.9 % (95 % CI
25.2–30.8) compared to the Western Cape which has a
prevalence of 7.8 % (95 % CI 5.5–10.9) [1]. In South
Africa, young women acquire HIV at least 5 to 7 years
earlier than their male peers and bear a disproportion-
ate burden of HIV [2, 3]. In 2012, the HIV prevalence
in young women in the 15–24 year age group was
11.4 % (95 % CI 9.8–13.2) compared to 2.9 % (95 % CI
2.1–3.9) in young men in the same age group [1].
In addition to household surveillance, the South African
National Department of Health (SA DOH) conducts an-
nual anonymous seroprevalence surveys among pregnant
women utilizing public sector health care facilities across
South Africa. These surveys have captured increases in
HIV prevalence over time from 0.8 % in 1990 reaching
30.2 % in 2010 and stabilizing to 29.5 % in 2011 and 2012
[3, 4]. Similar to the household data, the data from preg-
nant women mask geographical variations and in 2012 the
HIV prevalence in KZN was 37.4 % (95 % CI 36.0 – 38.7)
in contrast to 16.9 % (95 % CI 13.8 – 20.5) in the Western
Cape. Additionally, seven of the nine districts within KZN
have recorded antenatal HIV prevalence above 38.0 %
with the uMgungundlovu district having a prevalence of
40.7 % [5]. These trends in HIV prevalence continue both
provincially and nationally [5].
Prospective cohort studies in KZN have demonstrated
that young women are particularly vulnerable to HIV [1, 3].
Across urban and rural areas, high HIV incidence rates
have been observed: 6.5/100 women years of observation
(wy) (95 % CI 4.4–9.2) in Vulindlela, 6.4/100 wy (95 % CI
2.6–13.2) in Durban [6], 14.8/100 wy (95 % CI 9.7–19.8) in
Ladysmith, 6.3/100 wy (95 % CI 3.2–9.4) in Edendale,
and 7.2/100 wy (95 % CI 3.7–10.7) in Pinetown [7].
Recent data from the CAPRISA 004 tenofovir gel trial
has shown that HIV incidence rates in 18–40 year old
urban (Durban) and rural (Vulindlela) women in the
placebo gel arm was 9.0/100wy (95 % CI 5.3–14.3) and
9.1/100wy (95 % CI 6.6–12.3) respectively [8].
Using the Limiting-Antigen Avidity Assay (LAg-Avidity
EIA) of measuring HIV incidence from cross sectional
sampling, at the national level, HIV incidence measures
show differential HIV transmission dynamics. In 2012,
HIV incidence was 2.3 % (95 % CI 1.8–2.7) in women aged
15–49 years, which was 1.7 times higher than the 1.21 %
(95 % CI 0.9–1.5) in men. In 15–24 year old women, HIV
incidence was 2.5 % (95 % CI 2.0–3.0), which was more
than four times higher than the 0.6 % (95 % CI 0.5–0.7) in
men of the same age [1]. These rates suggest that HIV re-
mains exceptionally high and the underlying dynamics of
transmission within communities is not well understood.
To counter these high rates, the South African govern-
ment launched the national HIV prevention and treatment
campaign in 2010 [9], which aimed to increase HIV coun-
selling and testing (HCT) and antiretroviral therapy (ART)
uptake, rigorous implementation of prevention of mother-
to-child transmission (PMTCT) of HIV, roll out of
voluntary medical male circumcision (VMMC) and the
provision of post exposure prophylaxis (PEP) [10]. These
programmes have resulted in some degree of success [11],
however, providing optimal coverage to prevent further
spread of HIV requires a nuanced understanding of the
underlying drivers of HIV transmission in conjunction with
programmes that are in place across the region. Strength-
ening the effectiveness of ART roll out requires advanced
monitoring of heterogeneous outcomes that are influenced
by variable rates of uptake, adherence and retention in
follow-up. In addition to ART [11] and early ART initiation
[12], known as ‘treatment-as-prevention’ (TasP) [13–16],
many biomedical interventions are undergoing evaluations
and could be implemented in the near future. These in-
clude vaginal microbicides [8]; oral [17–19] and long-acting
injectable [20] pre-exposure prophylaxis (PrEP); and struc-
tural measures such as conditional cash transfers (CCT)
[21, 22], all of which are crucial components of a compre-
hensive HIV prevention strategy that could potentially have
an impact on HIV incidence rates over time [23].
Given the imperative to scale-up HIV treatment, biomed-
ical and structural interventions, there is a tangible need for
independent mechanisms to monitor and determine which
programmes have the capacity to alter epidemic trajectories
in different geographical areas. In addition, as HIV preven-
tion interventions become increasingly available, demand
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for access and distribution to those in highest need is a
challenge for HIV programmers. Thus, better monitoring
of HCT programmes on service uptake, linkage to HIV care
and treatment, transmitted and acquired ART drug resist-
ance and co-morbidities are crucial for the associated bene-
fits on individuals and population levels [24, 25]. Measuring
HIV prevalence trends over time is a major part of national
and provincial strategic AIDS plans, however, these become
difficult to interpret because of increasing survival over
time amongst individuals on ART [26, 27]. This survival ef-
fect could limit the usefulness of using only HIV prevalence
data for surveillance of new infections. Therefore, there is a
need to measure HIV incidence to improve surveillance
systems as it provides a more sensitive method to monitor
trends in heterogenous epidemics [28].
Measuring HIV incidence is, however, challenging. HIV
incidence measured by the traditional follow-up of cohorts
of HIV-uninfected individuals or estimated using modeling
methods have their limitations [28]. Laboratory-based as-
says such as the LAg-Avidity EIA can be used to generate
cross-sectional incidence data and advances in the use of
such assays has been recognized [1]. However, these assays
require validation in different populations including geo-
graphical regions and the extent of ART use [29].
In order to sharpen and focus on delivering high quality
HIV services, there is a greater need to better understand
HIV transmission sexual networks that contribute to local
HIV diversity. Phylogenetic analysis [30–33] and geospa-
tial mapping [34, 35] of HIV-1 sequences are newer tools
which have substantially advanced our ability to track the
epidemic and intervene to prevent new HIV infections
[36]. These tools provide an opportunity to identify spatial
variation at regional, urban/rural, district and sub-district
levels and whether HIV “hotspots” are clustered in rela-
tion to structural, sociodemographic and behavioural fac-
tors. Furthermore identifying HIV transmission chains
within social sexual networks would provide empirical evi-
dence for understanding the dynamic heterogeneity of
HIV infection which to a significant degree is often
masked at a country level [37]. It is also important to
focus on “locations” [38] to get a better understanding of
what’s driving this heterogeneity so that prevention and
treatment efforts could be tailored and implemented
within discreet and broader communities; and target key
populations and high transmission areas (HTA).
We hypothesized that the intensified HIV programmatic
interventions, prevention and treatment efforts of the KZN
Provincial Department of Health (DoH), together with its
implementing partners, would lead to reductions in HIV
incidence among men and women in this region.
Aim
The aim of this study is to establish a population-level
HIV incidence Provincial Surveillance System (HIPSS) in
a household-based representative sample of men and
women in rural and peri-urban KZN and to use the data
to inform the local and national DoH on the design and
methodology of future HIV surveillance programs.
Objectives
The primary objective is to:
 assess the impact of programmatic intervention
efforts in a “real world”, non-trial setting on HIV
incidence.
The secondary objectives are to:
 estimate the prevalence of HIV, CD4 cell counts in
HIV infected individuals and proportion on ART
and ART naïve with detectable and undetectable
HIV-1 RNA viral load;
 measure prevalence of pulmonary tuberculosis (TB),
sexually transmitted infections (STI) and hepatitis B
and C infections;
 measure HIV incidence trends over time;
 compare cohort measurement of HIV incidence
with those obtained from cross-sectional sampling
and LAg-Avidity EIA;
 estimate community HIV-1 RNA viral load;
 estimate the spectrum of ART resistance in
prevalent and incident HIV infections;
 geospatially map HIV infections in relation HIV-1
RNA viral load to identify specific clusters of
infections and whether these contribute to enhanced
HIV transmission;
 characterize HIV-1 genetic diversity in this
populations and identify HIV transmission networks
as sources of infection;
 identify risk factors for HIV incidence at the
individual, household, and community levels.
Methods
Study setting
This study will be carried out in central KZN in Vulindlela
and Greater Edendale, two of the seven sub-districts in
the uMgungundlovu (Fig. 1 – Map of the study area)
Municipality. The region incorporates rural traditional set-
tlements or farmlands through to informal and peri-urban
living.
Vulindlela is a rural community with a population of just
over 150,000 predominantly Zulu speaking people. The
majority of the land belongs to the traditional authority
through the Ingonyama Trust and is made up of nine
wards, of which five are under the traditional leadership
and four are under the ward counsellors of the local
government municipal system. The Greater Edendale area
with a population of about 210,000 people is the second
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largest peri-urban area within KZN and is the main eco-
nomic hub within the uMgungundlovu district. It is linked
to Vulindlela by a dual carriage way known as the Edendale
Corridor. This route serves as the connection between
various outlying rural areas to the north of Pietermaritz-
burg. Much of the Greater Edendale Area is developed with
both formal and informal housing, supported in some areas
by ancillary land uses and facilities.
Fig. 1 Location of Greater Edendale and Vulindlela study area in KwaZulu-Natal, South Africa
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There are 16 primary health care clinics (PHC) in the
area, within which trained nurses provide much of the
health care. The PHCs are supported by three district
hospitals that cater to people in the western area of
KZN, including the study area. In addition, there are
about 60 community-based organizations in the district
representing a variety of civic interests such as youth,
women, religions and political parties. Several of these
organizations are currently providing HIV prevention
and home-based care services.
Study design
This study will establish two sequential, representative,
cross-sectional household surveys of 10,000 individuals per
round. The cross-sectional surveys will enroll individuals
15 to 49 years of age. Sequential embedded cohorts of HIV
negative individuals between the ages of 15 and 35 years
will be followed up prospectively and assessed for HIV in-
fection after 12 months. A schematic diagram representing
the overall study design is shown in Fig. 2.
Study population
According to national census data [39, 40], the study area
has an estimated 95,641 households with an estimated
total of 367,906 individuals. Of these, 176,418 (48.0 %) are
males and 191,515 (52.0 %) females. A total of 217,278
(59.1 %) are in the age range of 15–49 years and 164,302
(44.7 %) are in age range of 15–35 years.
Sampling strategy
A two-stage cluster-based sampling of enumeration areas
(EA) will be used to randomly select households. The sam-
pling frame has been triangulated from the 2011 Census
[40], the 2007 Community survey data (StatSA Community
Survey) [41], and aerial imaging of dwellings supplied by
the 2011 midyear estimates of Geo Terra Image (GTI).
These will determine the number of households at an EA
level.
EAs will be drawn randomly and within each EA, house-
holds will be drawn systematically with a random start in
a serpentine pattern. Study staff will identify households
and use a Global Positioning Systems (GPS) receiver to
record the geographic coordinates of each randomly
selected household. If households are not sampled for
reasons of abandonment, refusal to participate, or if the
members are away for an extended period of time, the
household on the right side of the selected house, when
facing its entrance, will be used as a replacement. All re-
placement households will be authorized by a supervisor.
Sampling will continue until 10,000 households have been
enrolled.
Once a household is selected, a handheld personal digital
assistant (PDA) will be used to compile a list of all the
individuals residing in the household. All individuals who
meet the eligibility criteria will be numbered and the PDA
will select one of these individuals at random to be included
in the study. Only one individual per household will be
enrolled. Should the selected individual refuse to participate
the next randomly selected individual may be enrolled in
the study. Should this second individual also refuse the
household will be replaced as described earlier.
Eligibility criteria
Men and women aged 15 to 49 years who reside in the
selected household, who are willing to participate and pro-
vide written informed consent (or parental consent/child
participant assent if < 18 years of age) in either English or
Zulu, and are willing to undergo all study procedures
including provision of clinical specimens (peripheral blood,
urine, sputum-if indicated and for females, self-collected
vulvo-vaginal swabs) will be eligible. Those who are non-
residents of the household, who refuse to participate and/or
Fig. 2 Study design and timelines
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provide samples, who cannot consent, are mentally chal-
lenged, or who plan to move within 12 months will be
excluded. The longitudinal follow-up will include all HIV
negative enrolled individuals 15 to 35 years of age from the
cross-sectional survey.
Statistical considerations and sample size calculation
The sample size of this study provides 84 % power to detect
a 30 % reduction in HIV incidence rate at a 5 % significance
level, given an HIV prevalence of 20 %, loss-to-follow-up of
15 % per annum and an initial HIV incidence rate of 3 per
100 person years.
To compare the changes in HIV incidence over time, the
HIV incidence rate will be calculated for each cohort. The
incidence rate ratio of the two cohorts will be calculated to
quantify the change in HIV incidence between the two time
periods. The assumptions for various study outcomes have
been summarized in Table 1.
Study procedures
Recruitment
Study staff will approach the randomly selected house-
holds, make appropriate introductions, identify the head
of household or designee and provide study information.
A household composition form will be completed to
capture age, gender, and basic socio-demographic profile
of all usual household members, including questions on
household economic status, food security, access to
health services, health status and changes in compos-
ition and deaths in the last 12 months. The PDA has
been programmed to randomly select one individual
who meets the eligibility criteria and that person will be
asked to participate in the study. Those who agree to
participate will be prepared for baseline assessments and
enrolment.
Baseline and follow up assessments
Eligible participants will receive study information; provide
consent (or assent), biometric fingerprints, and locating in-
formation before enrolment into the study. Each participant
will be assigned a unique study number that will be linked
to the structured questionnaire to be administered by study
staff using the PDA. Study staff with training in phlebotomy
will collect peripheral blood sample (25 ml). Participants
will be guided to collect sputum (if indicated based on the
presence of any signs and symptoms of TB), 10–20 ml of
first-pass urine sample (males), and self-collected vulvo-
vaginal swab samples (females).
Study staff will administer questionnaires to obtain
 demographic variables including age, gender, marital
status, socioeconomic status, occupation,
employment and educational status,
 psycho-social variables including knowledge/
motivational issues, capabilities, social norms and
affective states/situational contexts related to sexual
risk behavior and indicators of depression;
 behavioural variables including partner
characteristics, number, type (regular/casual), and
concurrency of sex partners, condom use, alcohol
use, knowledge of own and sex partner(s) HIV
Table 1 Number of enrolled participants required to achieve the targeted effective number of person years of follow-up
Time point
T1 and T2 T3 and T4
Cross sectional survey (Baseline) (age range 15–49 years)
Number at baseline 10,000 10,000
HIV Prevalence 20 % 20 %
Number expected to be HIV negative 8000 8000
Longitudinal follow-up cohort (age range 15–35 years)
Design effect 1.1 1.1
Number of individuals in the HIV negative cohort 6400 6400
Assumed HIV Incidence rate 3 % 3 % reduced by 30 %
Loss to Follow-up adjustment 15 % 15 %
Number expected to be retained in cohort 5440 5440
Number of HIV endpoints assumed 163 114
Total number of endpoints assumed across both cohorts 277
Probability of Correct Inference 84 % 84 %
T1 = Cross sectional Survey 1
T2 = Embedded cohort 1
T3 = Cross sectional Survey 2
T4 = Embedded cohort 2
Kharsany et al. BMC Public Health  (2015) 15:1149 Page 6 of 11
status, engagement in transactional sex and
exposure to intimate partner violence;
 HIV status variables, including HIV testing history
and date of last HIV test, HIV test results and
linkages to HIV medical and psychosocial care, ART
use, exposure to and treatment for TB and STI;
 contraceptive use (females only); and
 male circumcision status (males only), including
whether circumcised, and acceptability and access to
VMMC. Exposure to any informational, educational,
behavioural and/or biomedical prevention, treatment
and psychosocial support programmes for HIV
through the DoH, community organisations and/or
PEPFAR partners in the district will be captured.
Participants completing the baseline survey will be in-
formed that they might be contacted for the follow-up
survey in approximately 12 months. Participants, eligible
for the cohort will be contacted. Study staff will verify the
participant’s identity and administer a follow-up question-
naire using the PDA and collect samples for follow-up
assessments. Any refusals and lack of retention for any
reason will also be captured.
Access to health care
HCT services will be made available to participants and
family members, with referral systems to access care, sup-
port and treatment. Participants with signs and symptoms
of STIs and/or TB will receive a symptom specific referral
note to district PHC services for care and services. A key
component of this survey is related to the provision of
HIV test results to participants. All participants will be
provided with a barcoded card and informed that they
have an opportunity to access their HIV test results from
the samples that have been collected from the survey. The
laboratory results for HIV serology, CD4 cell count, HIV-1
RNA viral load, STIs and TB will be sent to all PHC clinics
in the study area for participants to access using their
barcoded card. In collaboration with the DoH, all PHC
clinic staff have been trained to receive study partici-
pants, provide results with appropriate counselling and
follow-up care. The number of individuals referred will
be recorded to determine the number of people acces-
sing these services.
Outcomes and analysis
The primary outcome will be HIV incidence measured
through prospective follow-up of the cohorts at 12 months
following enrolment.
Analysis of the primary objective
HIV incidence will be estimated at two time points in this
household-based representative sample of men and women.
Only participants who test HIV negative at enrolment will
be included in this analysis. The person-years in follow-up
will be calculated as the difference between the date of the
enrolment HIV test and the 12-month HIV test. The date
of HIV infection will be assumed to be the midpoint be-
tween the last HIV negative test and the first HIV positive
test. To achieve a population HIV incidence rate, the total
number of new HIV infections will be divided by the total
number of person-years. Incidence rates will be presented
in conjunction with 95 % CI, and stratified by age group
and gender. The incidence rate ratio (IRR) of the two
cohorts will be calculated to quantify the change in HIV
incidence between the two time periods, including 95 % CI
calculated using Poisson approximations (for incidence) or
the F-distribution for IRR. Comparisons of HIV incidence
from the two cohorts over two time points will assume a
Poisson distribution of new HIV infections in the follow-up
time in each cohort.
Analysis of secondary objectives
 HIV linkage to care and treatment cascade: The
proportion of HIV-positive men and women in
HIV care, on ART by self-report and laboratory
measurement of ARV, and with viral suppression
or detectable virus will be determined. Logistic
regression will be used to assess any differences in
proportions of men and women accessing ART.
These analyses will be stratified by CD4 cell counts
and adjusted for potential confounders.
 Associations of new HIV infections: The
association between new HIV infections and several
baseline predictive variables will be assessed.
Survival analysis methods will be used to calculate
hazard ratios in follow-up time varies within the
sample, or multivariate logistic regression if
follow-up durations are similar. Variables in the
baseline survey to be included in the analysis will be
demographic information (age, gender and area of
residence), psycho-social variables, and partner
characteristics, situational factors associated with
sexual practices, sexual behavior, HCT, VMMC,
condom use, and exposure to behaviour change
information, training and communication.
Household-level variables will also be used as
predictors of HIV acquisition.
 Prevalence and incidence of STIs, Hepatitis B
and C: The prevalence of STIs including gonorrhoea,
chlamydia, trichomoniasis, herpes simplex virus
type 2 (HSV-2) antibodies, syphilis, and human
papillomavirus (HPV) infection will be measured.
Hepatitis B and C prevalence will be measured. All
estimates will include 95 % CI and stratification by
age and sex. The incidence of STIs and Hepatitis B
and C will be measured in participants who test
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negative for these infections at enrolment.
Person-years of follow-up, date of infection and
incidence rates will be calculated as above for HIV.
 Prevalence and incidence of pulmonary TB: The
case definition of TB will be a positive result on the
automated diagnostic test, the GeneXpert MTB/RIF
for the identification of M. tuberculosis DNA and
resistance to rifampicin by nucleic acid amplification
technique. Prevalence by age and sex will be
calculated for both HIV positive and negative
participants. Only participants who tested negative
for TB at enrolment will be included in TB
incidence measures. Incidence rates, 95 % CIs, date
of infection, and stratifications will be done as for
other infections.
 Performance of laboratory assays for HIV
incidence measurement: The LAg-Avidity EIA
assay derived incidence will be compared to the
incidence rate derived from the prospective cohort
using parameters recommended for the assay. We will
use the latest available data on false recent rates (FRR)
of the chosen algorithm (using data from CDC and
the Consortium for the Evaluation and Performance
of HIV Incidence assays) to estimate the locally
applicable FRR [42]. Assay-based HIV incidence will
be calculated as the number of recent infections
divided by the population at risk (those testing
HIV-negative plus those recently seroconverting),
annualized by multiplying by 365 divided by the
estimated length of mean seroconversion duration for
the assay (130 days for the LAg-Avidity EIA assay;
95 % CI 118–142 days).
 Measurement of community HIV viral load: The
mean viral load of a community will be used as an
indicator of ART uptake, coverage and continued
HIV transmission. The community viral load will be
calculated as the arithmetic mean of viral load
measures in HIV seropositive participants and will
provide a baseline measurement for determining
impact of programmes on increasing ART use and
viral suppression. Undetectable viral load will be
counted as 50 copies when calculating the mean.
 Prevalence and incidence of transmitted HIV
drug resistance: The 1.3 kb fragment of the HIV-1
pol gene will be amplified for the detection of
genotype resistance mutations. The prevalence of
drug resistance will be determined by calculating
point prevalence with 95 % CIs according to
threshold levels of low (< 5 %), moderate (5–15 %)
and high (> 15 %) in individuals with prevalent HIV
infection at baseline. Results will be stratified by
self-reported ART status and history. In individuals
with incident infection during follow-up, the incidence
of transmitted resistance will be measured.
 Geospatial mapping of HIV infections: Using the
household GPS co-ordinates, prevalent and incident
HIV infections will be mapped to identify location of
infections. Using a two-dimensional Gaussian kernel,
prevalent and incident infections will be mapped
across continuous geographical space. The Kulldorff
spatial scan statistic (Bernoulli model) will be used
to identify clusters of infections (P < 0.05) to
determine any geographical heterogeneity.
 Identifying transmission linkages constituting
the sexual networks driving high HIV incidence:
The genetic diversity of the viruses in these
populations will be used for the identification of
transmission clusters. Phylogenetic trees will be
generated using maximum likelihood methods
and network analysis to characterize transmission
clusters and their members, describe the network
characteristics of these transmission chains and
analyze the contribution of HIV clusters to new
infections.
 Identifying socio-demographic, biological and
sexual risk behaviours: Multivariable analyses of
self-reported data will assess the extent of these
factors and their contribution to HIV prevalence
and incidence.
Ethical considerations
Extensive community engagement has been established
with local stakeholders including traditional leaders from
the community, service providers for health, social and
economic development in this catchment area, including
government and public and private organisations who
provide services related to education, psycho-social sup-
port, socio-economic support as well as treatment. In
addition, health-service providers from each of the PHCs
in the district have been trained to provide appropriate
care and management of participants referred to clinics.
All stakeholders are provided with information on the
South African HIV epidemic, availability and access to the
governments HIV prevention and treatment programmes
and the rationale for undertaking this study.
All study participants will provide written informed
consent (or parental consent/child participant assent if
< 18 years of age) in either English or Zulu prior to any
study related procedures. Inclusion of individuals under
the age of 18 years has been driven by the consistent
finding that HIV prevalence and incidence are consid-
erably high in this age group, particularly in females [6,
43]. Data on 15–24 year old prenatal women and those
from the general population show that HIV prevalence
and incidence remain higher in this age group com-
pared to males in the same age group [1, 4]. These data
underscore the need to continually monitor this sub-
group. In addition, there is a precedent and a
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framework in South Africa for individuals’ ≥ 15 years of
age to give informed consent for participation in sexual
reproductive health research. Whilst the age of consent
in South Africa for having an HIV test is 12 years, it is
theoretically possible to include those < 15 years in this
study; however, the ethical considerations related to
confidentiality, anonymity and protection of children
preclude their participation despite them being sexually
active and at risk for HIV infection. Separate studies
may be required for this sub-population.
The embedded cohort study sample is biased towards
the younger population, where most HIV incident infec-
tions are observed; this is intended to enhance the effi-
ciency of the study, rather than the inclusion of an older
population where fewer incident infections are expected
to occur. Persons with a stated intention to leave the study
area indefinitely may be more easily lost-to-follow-up.
Substantial attrition from these persons could reduce the
power of the study, and ultimately jeopardize the ability of
the study to detect differences in the key study outcomes.
Discussion
Recent reports suggest that South Africa has made
remarkable gains in the scale up of ART, leading to sub-
stantial reductions in mortality, increasing survival and
HIV prevalence [11]. Parallel to these gains there have
been a considerable decline in incident HIV infections.
However, despite these gains, HIV incidence remains
unacceptably high in this region [38]. The key question is
what intensity and coverage of HIV prevention and treat-
ment initiatives will be needed to significantly reduce HIV
incidence and maintain effective control over the longer
term to eliminate HIV infection as an important public
health measure. As HIV transmission varies over time,
place, and population group, understanding where preva-
lent and incident HIV infections are located geographically,
and how they are being acquired (modes of transmission),
has been important for monitoring temporal trends of the
evolving pandemic, guiding the targeting of prevention
efforts, assessing the impact of interventions, and planning
for health care delivery needs [38, 44, 45]. This requires
increased efforts for regular, systematic and cost-effective
monitoring strategies.
In many countries, the extent and magnitude of HIV in-
fection remains uncertain as a result of insufficient disease
surveillance systems and diagnostic capabilities. This has
improved dramatically through the development of HIV
antibody testing, which has helped countries to identify
emerging HIV epidemics, set up surveillance systems to
better understand the modes of transmission, track and
understand the natural history of infection and provide a
reasonable picture of the evolving epidemic. South Africa
has robust country level HIV surveillance systems to moni-
tor HIV prevalence among pregnant women attending
public sector primary health care clinics [4] and in the
general population through the household surveys [1].
These have over time improved the reliability of national
HIV prevalence estimates and provide robust information
on the evolving epidemic at a country level. However, a nu-
anced understanding of the heterogeneity of the epidemic
at the local level including in specific locations is limited,
and would be highly beneficial to maximize on limited
resources.
The establishment of this study will contribute to moni-
toring the uptake and impact of HIV prevention efforts and
extend into overall health impact. As opposed to “efficacy”,
which measures a program’s effect under highly controlled
conditions, “impact” (or community-level effectiveness) is
the effect of a program on a population level as measured
by changes in incidence, prevalence, mortality, and/or other
ultimate outcomes of interest such prevalence of TB, STIs
and teenage pregnancy rates. As the KZN Provincial Gov-
ernment, PEPFAR partners and other local organizations
are scaling-up intensive, multi-pronged prevention inter-
ventions including HCT, VMMC, and early treatment for
HIV, it is important to collect localized and detailed infor-
mation about the HIV response in a geographic area that
has the ability to look more closely at associations between
the scale-up of prevention efforts and changes in HIV inci-
dence in a “real world”, non-trial setting at a population-
level.
Many methods, other than prospective cohorts, to esti-
mate HIV incidence have been developed in an attempt to
provide a more sensitive and reliable indicator of the
impact HIV prevention efforts. HIV incidence estimation
however poses methodological challenges and on-going
efforts are needed to strengthen our ability to accurately
measure incidence. Therefore, this study has the potential
to evaluate different laboratory assays including those that
are newly developed.
The activities, aims, and outcomes of the HIPSS study
would provide valuable information to the province to
enable the implementation of the surveillance strategy
across other districts and are aligned to the National and
Provincial AIDS Strategic plan [10], UNAIDS 90–90–90
targets [45] and PEPFAR’s Determined, Resilient, AIDS-
free, Mentored, and Safe (DREAMS) project [46] which
collectively aim to address risk behaviours, gender based
violence, enhance knowledge of HIV status, uptake of ART
and reduce HIV transmission. The HIPSS study will be
implemented in close consultation with the District Health
Management team and so approaches and results identified
as a priority will be aligned to the needs of the District,
Provincial and National health systems. This is key to
sustainability of HIV surveillance to monitor the epidemic
over time.
Our study has some limitations. As with all survey
data, there is the potential of underreporting of sensitive
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behavioural data. This is often due to a combination of
poor recall, participants being untruthful, inadequacies
in measurement instruments, social desirability bias, and
sampling bias. The extent of underreporting is somewhat
mitigated by the use of PDA-based interviews since the
presence of the PDA enhances participants’ perceptions
of privacy and thus increase responses to sensitive
questions. Recall bias is also limited as some response
categories act as triggers for follow-up questions.
However, setting up district level surveillance sys-
tems will provide detailed information about the HIV
response in the specific geographic areas and the abil-
ity to look more closely at associations in scale-up of
prevention efforts on changes in HIV incidence. While
the South African National HIV Prevalence, Incidence,
Behaviour and Communication Survey is extremely
valuable to monitor the HIV epidemic in South Africa
its large geographic coverage and cross sectional meth-
odology makes it difficult to assess more localized inci-
dence dynamics with any statistical power.
In summary, South Africa has one of the highest HIV
prevalence and incidence rates in the world. The province
of KZN with the highest infection rate in the country is
taking a leading role in implementing a combination of
programmes for HIV prevention and treatment at an
unprecedented pace. It is vital to describe changes in the
rate of new HIV infections resulting from implementation
of these interventions. The HIPSS study described in this
protocol seeks to document changes in HIV incidence
and examine factors that may contribute to these changes
so that other districts, provinces, countries and programs
can develop and implement HIV surveillance strategies to
rapidly monitor anticipated changes in HIV incidence.
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